Japan's SBC Medical Q2 revenue beats on AI-powered support expansion
SBC•Q2 results beat expectations
Japan's SBC Medical Group Holdings Inc said fiscal second-quarter revenue rose 13% year over year, beating analyst expectations.
Net income attributable to SBC Medical surged 335% year over year, with basic earnings per share up 400%.
The company said earnings growth was driven by AI-enabled service enhancements and successful fee increases.
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the business support services peer group is "buy".
Wall Street's median 12-month price target for SBC Medical Group Holdings Inc is $8.50, about 165.6% above its August 12 closing price of $3.20.
The stock recently traded at 7 times the next 12-month earnings, versus a P/E of 7 three months ago.
Outlook and growth initiatives
The company expects annual service fees to rise by about $15 million if initiatives are realized.
SBC Medical plans to accelerate global growth via U.S. and ASEAN expansion.
It also plans to deepen its multi-brand strategy in aesthetic dermatology and expand its non-aesthetic business.
